Literature DB >> 15385951

Gene therapy progress and prospects: episomally maintained self-replicating systems.

M Conese1, C Auriche, F Ascenzioni.   

Abstract

The use of nonviral gene therapy vectors has been hampered by low level of transfection efficiency and lack of sustained gene expression. Episomal self-replicating systems may overcome these hurdles through their large packaging capacity, stability and reduced toxicity. This article reviews three classes of episomal molecules that have been tested with possible therapeutic genes: (1) self-replicating circular vectors, containing the Epstein-Barr virus (EBV) elements oriP and EBNA1; (2) small circular vectors containing scaffold/matrix attachment regions (S/MARs) as cis-acting elements to maintain the episomal status of the vector; (3) chromosomal vectors, based on the functional elements of the natural chromosomes. The studies reported validate the use of episomal vectors to obtain stable and prolonged gene expression, although reveal some limitations that necessitate additional work.

Entities:  

Mesh:

Year:  2004        PMID: 15385951     DOI: 10.1038/sj.gt.3302362

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  16 in total

Review 1.  Artificial and engineered chromosomes: developments and prospects for gene therapy.

Authors:  Brenda R Grimes; Zoia Larin Monaco
Journal:  Chromosoma       Date:  2005-10-15       Impact factor: 4.316

Review 2.  Plasmid engineering for controlled and sustained gene expression for nonviral gene therapy.

Authors:  Ethlinn V B van Gaal; Wim E Hennink; Daan J A Crommelin; Enrico Mastrobattista
Journal:  Pharm Res       Date:  2006-05-26       Impact factor: 4.200

3.  Robust in vivo transduction of a genetically stable Epstein-Barr virus episome to hepatocytes in mice by a hybrid viral vector.

Authors:  Sean D Gallaher; Jose S Gil; Oliver Dorigo; Arnold J Berk
Journal:  J Virol       Date:  2009-01-21       Impact factor: 5.103

4.  Interspecific transfer of mammalian artificial chromosomes between farm animals.

Authors:  Filomena Monica Cavaliere; Gian Luca Scoarughi; Carmen Cimmino
Journal:  Chromosome Res       Date:  2009-07-23       Impact factor: 5.239

5.  E2F in vivo binding specificity: comparison of consensus versus nonconsensus binding sites.

Authors:  Alina Rabinovich; Victor X Jin; Roman Rabinovich; Xiaoqin Xu; Peggy J Farnham
Journal:  Genome Res       Date:  2008-10-03       Impact factor: 9.043

6.  Dominant-negative effects of COL7A1 mutations can be rescued by controlled overexpression of normal collagen VII.

Authors:  Anja Fritsch; Sashko Spassov; Susanne Elfert; Andreas Schlosser; Yannick Gache; Guerrino Meneguzzi; Leena Bruckner-Tuderman
Journal:  J Biol Chem       Date:  2009-09-02       Impact factor: 5.157

7.  Sustained gene expression in the retina by improved episomal vectors.

Authors:  Sofia M Calado; Ana V Oliveira; Susana Machado; Rudolf Haase; Gabriela A Silva
Journal:  Tissue Eng Part A       Date:  2014-05-09       Impact factor: 3.845

8.  Expanding the genetic code of the human hematopoietic system.

Authors:  Sida Shao; Minseob Koh; Peter G Schultz
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-06       Impact factor: 11.205

9.  Stable S/MAR-based episomal vectors are regulated at the chromatin level.

Authors:  Federico Tessadori; Kang Zeng; Erik Manders; Martijn Riool; Dean Jackson; Roel van Driel
Journal:  Chromosome Res       Date:  2010-11-16       Impact factor: 5.239

Review 10.  The future of human DNA vaccines.

Authors:  Lei Li; Fadi Saade; Nikolai Petrovsky
Journal:  J Biotechnol       Date:  2012-09-07       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.